Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary: Purpose: Levetiracetam (LEV) is a highly effective antiepileptic agent. A clinically relevant psychiatric complication of LEV treatment, however, is the provocation of irritability and aggression. Recent behavioral research indicates that personality traits may predispose to these side effects. To assess the genetic basis of the adverse psychotropic profile of LEV, a candidate gene‐based two‐stage association study was conducted. Methods: Polymorphisms were a priori selected according to their relevance for impulsivity and reactive‐impulsive aggression. Based on data from both stages, a Bonferroni‐corrected joint meta‐analysis was computed. Key Findings: Stage 1 analysis included 290 patients with epilepsy and revealed a higher load of adverse psychotropic side effects of LEV in patients carrying genetic variants associated with decreased dopaminergic activity: rs1611115 (dopamine‐β‐hydroxylase, DBH), rs4680 (catechol‐O‐methyltransferase, COMT), and rs1800497 (dopamine receptor D2‐associated ANKK1 TAQ‐1A). Stage II analysis including 100 patients with epilepsy, and joint meta‐analysis confirmed the effect of the rs1800497 polymorphism (Bonferroni corrected significance of the joint meta‐analysis, p = 0.0096). Significance: Confirming the suggestion from behavioral observations that patients might be predisposed to develop irritation and aggression under treatment with LEV, the findings provide first evidence of an association of genetic variation in dopaminergic activity and the risk for psychiatric complications of LEV treatment. Replication and further work is required to prove a true causal relationship. Overall, the pharmacogenomic approach to behavioral side effects may provide a future tool to predict adverse psychotropic effects related to antiepileptic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A
Brunner, H. G., Nelen, M., Breakefield, X. O., Ropers, H. H., & van Oost, B. A. (1993) · Science · doi:10.1126/science.8211186 · Cited by 1,644
Skol, A. D., Scott, L. J., Abecasis, G. R., & Boehnke, M. (2006) · Nature Genetics · doi:10.1038/ng1706 · Cited by 1,286 · cited 5×
“Finally, to increase statistical power, genetic association was tested through a joint meta-analysis (Skol et al., 2006; Terracciano et al., 2010).”
BackgroundMethodInfluentialGogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864 · cited 2×
“, 1982), catechol-O-methyltransferase (COMT) (Gogos et al., 1998), and monoamine oxidase (MAO) (Brunner et al.”
BackgroundThe Dopamine D2 Receptor Locus as a Modifying Gene in Neuropsychiatric Disorders
Comings, D. E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470130073032 · Cited by 587 · cited 5×
“Domschke K, Sheehan K, Lowe N, Kirley A, Mullins C, O’Sullivan R, Freitag C, Becker T, Conroy J, Fitzgerald M, Gill M, Hawi Z. (2005) Association analysis of the Monoamine Oxidase A and B genes with Attention Deficit Hyperactivity Disorder (ADHD) in an Irish sample: preferential transmission of the MAO-A 941G allele t…”
BackgroundInfluentialCaspi, A., Langley, K., Milne, B., Moffitt, T. E., O’Donovan, M., Owen, M. J., Polo Tomas, M., Poulton, R., Rutter, M., Taylor, A., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.24 · Cited by 221 · cited 2×
“Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam *1Christoph Helmstaedter, y1Yoan Mihov, zMohammad R. Toliat, zHolger Thiele, zPeter Nuernberg, xSusanne Schoch, *Rainer Surges, *Christian E. Elger, *{Wolfram S. Kunz, and yRené Hurlemann Departments o…”
BackgroundGenetics of human aggressive behaviour
Craig, I. W., & Halton, K. E. (2009) · Human Genetics · doi:10.1007/s00439-009-0695-9 · Cited by 213 · cited 4×
“…behavioral phenotype often classified as either instrumental-proactive or reactive-impulsive, with the former being goal-directed and characterized by a lack of empathy and remorse and the latter resulting from a loss of inhibitory self-control following anger outbursts (Craig & Halton, 2009).”
BackgroundInfluentialHess, C., Reif, A., Strobel, A., Boreatti-Hümmer, A., Heine, M., Lesch, K.-P., & Jacob, C. P. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0138-0 · Cited by 104 · cited 2×
“, 2005; Hess et al., 2009) Zhang et al. (2005)”
Dopaminergic system genes in childhood aggression: Possible role for DRD2
Zai, C. C., Ehtesham, S., Choi, E., Nowrouzi, B., de Luca, V., Stankovich, L., Davidge, K., Freeman, N., King, N., Kennedy, J. L., et al. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.543431 · Cited by 78
Cited by
Depression and Anxiety in People with Epilepsy
Kwon, O.-Y., & Park, S.-P. (2014) · Journal of Clinical Neurology · doi:10.3988/jcn.2014.10.3.175 · Cited by 294
Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review
Brodie, M. J., Besag, F., Ettinger, A. B., Mula, M., Gobbi, G., Comai, S., Aldenkamp, A. P., & Steinhoff, B. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012021 · Cited by 288
The role of dopamine signaling in epileptogenesis
Bozzi, Y., & Borrelli, E. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00157 · Cited by 199
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“Finally, in another study, the presence of rs1611115, rs4680 and rs1800497 polymorphisms with adverse psychotropic side effects of LEV in patients with chronic epilepsy was found to be related with a decrease in dopaminergic activity [195].”
BackgroundForced normalization: A systematic review
Calle‐López, Y., Ladino, L. D., Benjumea‐Cuartas, V., Castrillón‐Velilla, D. M., Téllez‐Zenteno, J. F., & Wolf, P. (2019) · Epilepsia · doi:10.1111/epi.16276 · Cited by 66
Metadata
- Authors
- Helmstaedter, C., Mihov, Y., Toliat, M. R., Thiele, H., Nuernberg, P., Schoch, S., Surges, R., Elger, C. E., Kunz, W. S., & Hurlemann, R.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2012-08-06
- Volume
- 54
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2101442317
- Cited by
- 82
- References
- 8
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. https://app.cochat.ai/papers/10.1111/j.1528-1167.2012.03603.x
- The paper
- Helmstaedter, C., Mihov, Y., Toliat, M. R., Thiele, H., Nuernberg, P., Schoch, S., Surges, R., Elger, C. E., Kunz, W. S., & Hurlemann, R. (2013). Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia. https://doi.org/10.1111/j.1528-1167.2012.03603.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.